Stock Events

Stock Events

Filana Therapeutics 

M$30.76
345
+M$0.34+1.12% Tuesday 18:31

Statistics

Day High
30.79
Day Low
30.76
52W High
86
52W Low
30
Volume
128
Avg. Volume
4
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 12
M$67.15
Dec 10
M$24.81
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6MayExpected
Q4 2025
Next
-5.35
-4.91
-4.47
-4.03
Expected EPS
-4.0306718
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FLNA.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap26.03B
Biogen is a leading competitor in the Alzheimer's treatment market, directly competing with Cassava's simufilam.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly has developed donanemab, an Alzheimer's disease treatment, competing in the same space as Cassava Sciences.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a history of developing treatments for neurological disorders, including Alzheimer's, making it a competitor.
AC Immune SA
ACIU
Mkt Cap280.9M
AC Immune SA focuses on developing treatments for neurodegenerative diseases, including Alzheimer's, directly competing with Cassava.
Annovis Bio
ANVS
Mkt Cap64.65M
Annovis Bio operates in the Alzheimer's and Parkinson's disease space, making it a competitor to Cassava Sciences.
Anavex Life Sciences
AVXL
Mkt Cap277.09M
Anavex Life Sciences Corp. is working on treatments for Alzheimer's disease, competing in the same market as Cassava.
Athira Pharma Inc
ATHA
Mkt Cap26.62M
Athira Pharma focuses on regenerative therapies for Alzheimer's, positioning it as a competitor to Cassava Sciences.

About

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Show more...
CEO
Mr. Richard Jon Barry
Employees
30
Country
US
ISIN
US14817C1071

Listings

MX
MX
FLNA.MX
XNAS
US
SAVA
F
DE
PX91.F
BOATS
BOATS
SAVA.BOATS

0 Comments

Share your thoughts

FAQ

What is Filana Therapeutics stock price today?▼
The current price of FLNA.MX is M$30.76 MXN — it has increased by +1.12% in the past 24 hours. Watch Filana Therapeutics stock price performance more closely on the chart.
What is Filana Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Filana Therapeutics stocks are traded under the ticker FLNA.MX.
When is the next Filana Therapeutics earnings date?▼
Filana Therapeutics is going to release the next earnings report on May 06, 2026.
What were Filana Therapeutics earnings last quarter?▼
FLNA.MX earnings for the last quarter are -4.64 MXN per share, whereas the estimation was -5.35 MXN resulting in a +13.33% surprise. The estimated earnings for the next quarter are N/A MXN per share.
Does Filana Therapeutics pay dividends?▼
Yes, FLNA.MX dividends are paid en. The last dividend per share was 67.15 MXN. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Filana Therapeutics have?▼
As of April 08, 2026, the company has 30 employees.
In which sector is Filana Therapeutics located?▼
Filana Therapeutics operates in the Health Care sector.
When did Filana Therapeutics complete a stock split?▼
Filana Therapeutics has not had any recent stock splits.
Where is Filana Therapeutics headquartered?▼
Filana Therapeutics is headquartered in Austin, US.